

Counteracting the Disease Continuum in Hormone-Sensitive Prostate Cancer - Tweetorial #3

References

Tweet 3

Svensson J, Lissbrant IF, Gauffin O, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. *Scand J Urol*. 2021;55(1):1-8. doi:10.1080/21681805.2020.1851762

Tweet 5

Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol*. 2020;77(4):508-547. doi:10.1016/j.eururo.2020.01.012

Sridharan S, Steigler A, Spry NA, et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. *Radiother Oncol*. 2016;121(1):98-102. doi:10.1016/j.radonc.2016.07.021

Tweet 6

Ali A, Hoyle A, Haran AM, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol*. 2021;7(4):555-563. doi:10.1001/jamaoncol.2020.7857

Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J Med*. 1998;339(15):1036-1042. doi:10.1056/nejm199810083391504

Fizazi K, Tran N, Fein LE, et al. Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). *J Clin Oncol*. 2019;37(7_suppl):141-141. doi:10.1200/JCO.2019.37.7_suppl.141

Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHARTED trial. *J Clin Oncol*. 2018;36(11):1080-1087. doi:10.1200/jco.2017.75.3657

Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. *J Clin Oncol*. 2008;26(36):5936-5942. doi:10.1200/jco.2007.15.9830

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med*. 2015;373(8):737-746. doi:10.1056/NEJMoa1503747

Tweet 8

Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). *Prostate*. 2018;78(12):889-895. doi:10.1002/pros.23645

Gravis G, Boher J-M, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. *J Clin Oncol*. 2015;33(7_suppl):140-140. doi:10.1200/jco.2015.33.7_suppl.140

Tweet 10

Reiter RE. Oligometastatic Disease: Definitions and Concepts. Presented at: Advanced Prostate Cancer Consensus Conference: APCCC; August 29-31, 2019 2019; Basel/Switzerland. Accessed August 26, 2021. <https://www.apccc.org/apccc2019/scientific-programme-and-panel/scientific-programme-and-slides/slides.html>

Tweet 11

Ost P, Reynnders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. *J Clin Oncol*. 2018;36(5):446-453. doi:10.1200/JCO.2017.75.4853

Tweet 13

Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of Oligometastatic Prostate Cancer. *Appl Radiat Oncol*. 2020;9(3):6-10.

Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. *JAMA Oncol*. 2020;6(5):650-659. doi:10.1001/jamaoncol.2020.0147

Tweet 14

Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol*. 2020;77(4):508-547. doi:10.1016/j.eururo.2020.01.012

Glossary

ADT, androgen deprivation therapy
APCCC, Advanced Prostate Cancer Consensus Conference
BCR, biochemical recurrence
BM, bony metastasis
CI, confidence interval
CT, computed tomography
DMFS, distant metastases-free survival
FFS, failure-free survival
HCP, healthcare provider
HR, high risk
HV, high volume
LV, low volume
M1, metastatic
MDT, metastases-directed therapy
Metach, metachronous
Mets, metastases
mCRPC, metastatic castration-resistant prostate cancer
mHSPC, metastatic hormone-sensitive prostate cancer
mOS, median overall survival
mPCa, metastatic prostate cancer
mTTR, median time to resistance
nmCRPC, nonmetastatic castration-resistant prostate cancer
nmHSPC, nonmetastatic hormone-sensitive prostate cancer
N+, node positive
NRLN, nonregional lymph node
OS, overall survival
PCa, prostate cancer
PDT, prostate-directed therapy
PET, positron emission tomography
PFS, progression-free survival
PSMA, prostate-specific membrane antigen
RT, radiation therapy
SBRT, stereotactic body radiotherapy
SOC, standard of care
Synch, synchronous
TTR, time to resistance
w/, with